Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention
Using an established pharmacokinetic/pharmacodynamic tissue model of tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis (PrEP), we predict that adding a fourth day of dosing to the 3-day IPERGAY on-demand PrEP regimen (currently approved for men/transgender women who have sex with men) will be efficacious for on-demand dosing in cisgender women.
Authors
- Nathan Engel (ORCID: https://orcid.org/0009-0003-6948-5202)
- Mackenzie L Cottrell
- Angela D M Kashuba
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1093/infdis/jiaf459
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00